The oral plaque psoriasis treatment ‘Sotyktu’ has entered its final stages to reimbursement in Korea.

According to Dailypharm’s coverage, BMS Korea accepted the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee’s deliberation results and accepted the condition of setting the price of its TYK2 inhibitor ‘Sotyktu (deucravacitinib)’ ‘below the evaluation amount’ that was made in DREC’s December meeting and is currently in drug pricing negotiations with the National Health Insurance Service.

As the first oral treatment option introduced for tie indication in 10 years, Sotyktu is designed to selectively target TYK2, inhibiting signaling of inte